"This investment underscores our commitment to the long-term development of our Laupheim site, a key part of Germany’s biotechnology landscape. This expansion will strengthen our competitive position in one of the world’s fastest-growing industries," said Benedikt von Braunmühl, CEO of Rentschler Biopharma. “Government support for a German national pharmaceutical strategy is an important signal for the industry as a whole. While our focus remains on strengthening global partnerships, this investment in our German site plays a crucial role in ensuring supply chain reliability and advancing our long-term growth strategy."

The planned four-story buffer media station, covering 34,000 m², will include three media tanks and six buffer tanks and is scheduled to be operational by 2028. The new facility will be seamlessly integrated with the existing infrastructure, offering faster and more efficient processes, as well as ergonomically designed workstations, providing an optimal working environment for employees, Rentschler stated.

“As a CDMO, it is our responsibility to support our clients in transforming innovative ideas into life-saving biopharmaceuticals. Patients with rare and severe diseases rely on the therapies we develop and manufacture in partnership with our clients,” added Christiane Bardroff, Rentschler Biopharma’s chief operating officer.

According to Rentschler, detailed planning for the new building has already begun, and construction is scheduled to start in spring 2025. Completion and operational launch are planned by the end of 2027, allowing the full potential of the new buffer media station to be realized by 2028.